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Abstract
Objective: Second-generation antipsychotics (SGAs) cause weight gain and cardiometabolic abnormalities in children and
adolescents. Less well-investigated is the outcome of these adverse events following SGA discontinuation, which we
examined.
Methods: Medically healthy 7 to 17-year-old patients treated with risperidone for ‡ 6 months were enrolled and returned for
follow-up, 1.5 years later. Treatment history was extracted from the medical and pharmacy records. Anthropometric and
laboratory measurements were obtained at each research visit. Multivariable linear regression analysis and Fisher’s exact test
were used to compare participants who remained on risperidone at follow-up (Risp Cont Group) with those who had
discontinued SGA treatment (SGA Disc Group) and those who had switched to another SGA (SGA Cont Group). Correla-
tional analyses examined the association between change in age-sex specific body mass index (BMI) z score between study
entry and follow-up and change in cardiometabolic outcomes.
Results:The sample consisted of 101 participants (93% male) with a mean age of 11.7 – 2.6 years at study entry. The majority
had an externalizing disorder and received 0.03 – 0.02 mg/kg/day of risperidone, for 2.5 – 1.6 years. At follow-up, 18%
(n = 18) were in the SGA Disc Group and 9% (n = 9) were in the SGA Cont Group. BMI z score decreased in the SGA Disc
Group, remained unchanged in the Risp Cont Group (n = 74), and increased in the SGA Cont Group. Importantly, the change
in BMI z score between study entry and follow-up was significantly correlated with the change in systolic and diastolic blood
pressure z scores, heart rate, waist circumference, percent body fat, inflammatory markers, fasting total insulin, homeostatic
model assessment insulin resistance index (HOMA-IR), C-peptide, total, low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) cholesterol, triglycerides, triglycerides/HDL ratio, and leptin.
Conclusions: Following several years of treatment, risperidone discontinuation is associated with a reversal of the excessive
weight gain, mediated by a negative energy balance, and a corresponding improvement in cardiometabolic parameters.
Introduction
Second-generation antipsychotic medications (SGAs) arewidely used in children and adolescents (Crystal et al. 2009,
Olfson et al. 2010, 2012). Although their introduction has allowed
targeting of severe psychopathology, much has been written about
their propensity to cause significant weight gain, predisposing to
cardiovascular disease because of ensuing cardiometabolic abnor-
malities, such as insulin resistance and dyslipidemia (Newcomer
2005, Vitiello et al. 2009; De Hert et al. 2011; Bobo et al. 2013).
However, in children and adolescents, SGAs are primarily prescribed
for externalizing disorders, that is, attention-deficit/hyperactivity
disorder (ADHD) and disruptive behavior disorders, in which
symptoms of irritability and aggressive behavior predominate
(Maglione et al. 2011; Olfson et al. 2010, 2012). Consequently,
SGA use in this age group may be more time limited. Based on a
randomized discontinuation trial examining the need for risper-
idone maintenance therapy in youth with disruptive behavior, it
was estimated that 52.9% of those switched to placebo would
remain relapse-free for the following 6 months (as compared with
70.7% of those continued on risperidone) (Reyes et al. 2006).
Therefore, whereas risperidone was statistically more effective at
preventing relapse, disruptive behavior remained well controlled in
a substantial number of placebo-treated youths (Reyes et al. 2006),
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suggesting that many children and adolescents can tolerate dis-
continuing the SGA without clinical relapse. Clearly, however, this
is not the case with all psychiatric disorders affecting youths; for
example, discontinuing risperidone led to rapid resurgence of ag-
gression in children and adolescents with autistic disorder, imply-
ing that treatment for extended periods in this condition is
necessary (Research Units on Pediatric Psychopharmacology
Autism Network 2005).
An increasing number of randomized clinical trials and observa-
tional studies have documented the magnitude of weight gain in
SGA-treated youths following short- and long-term treatment (Cor-
rell et al. 2009; De Hert et al. 2011; Calarge et al. 2012a,b). Although
reliable predictors of SGA-induced weight gain remain largely elu-
sive, weight at the onset of treatment, prior SGA trials, the dose of
certain SGAs, and perhaps some genetic variants may account for a
portion of the interindividual susceptibility to this adverse event
(Lipkovich et al. 2008a,b; Calarge et al. 2009c; Correll et al. 2009;
Gebhardt et al. 2009; Gentile 2009; Calarge et al. 2012a; Gohlke et al.
2012; Malhotra et al. 2012; Mankoski et al. 2013). In contrast, much
less is known about the reversibility of excessive weight after SGA
discontinuation. The resistance of idiopathic obesity to behavioral
and noninvasive medical interventions has been disappointing.
Therefore, it would be of clinical interest to establish whether SGA
discontinuation is associated with reversal of the excessive weight
gain trajectory and of associated cardiometabolic abnormalities.
Suggestive evidence for normalization of weight following SGA
discontinuation in youths comes from the study by Reyes et al. cited
earlier (Reyes et al. 2006). Those youths who were randomized to
placebo saw their elevated age-sex-specific weight z score nearly
return to the baseline level. Similarly, in a small cohort, Lindsay
et al. also showed that risperidone discontinuation led to a decrease
in excessive body mass index (BMI) z score (Lindsay et al. 2004).
However, in both studies, treatment with risperidone had lasted < 1
year, leaving unanswered whether risperidone discontinuation
following long-term treatment would similarly be associated with a
normalization of anthropometric outcomes. Furthermore, the im-
pact of the resolution of excessive weight on cardiometabolic pa-
rameters was not assessed. Therefore, using data from an
observational study that enrolled participants on chronic risper-
idone treatment, we examined the following questions: 1) Does
continued risperidone treatment lead to additional developmentally
inappropriate weight gain? 2) Does its discontinuation result in
normalization of anthropometric and cardiometabolic parameters?
3) Are there baseline characteristics that may distinguish those who
continue versus those who discontinue risperidone treatment?
Methods
Participants
As previously described (Calarge et al. 2009a; Calarge et al.
2012a), the primary aim of this study was to investigate the car-
diometabolic, hormonal, and skeletal adverse effects of risperidone
during long-term use in children and adolescents. Therefore, 7–17-
year-old patients treated with risperidone for ‡ 6 months were en-
rolled, irrespective of their primary psychiatric diagnosis or indi-
cation for risperidone. Concurrent treatment with additional
psychotropics at study entry, but not with other antipsychotics, was
allowed. Participants with neurological or medical conditions that
could confound the cardiometabolic assessments were excluded
(e.g., seizure disorder, hypothyroidism, dyslipidemia, diabetes) as
were pregnant females and those receiving hormonal contracep-
tion. Eighteen months after study entry, the participants were in-
vited to return for a follow-up research visit, at which time study
entry assessments were repeated.
Procedures
This study was approved by the local Institutional Review Board.
Written assent was obtained from children £ 14 years old and written
consent was obtained from adolescents and parents or guardians.
Start and stop dates of each psychotropic, changes in the dosage
and formulation, and the indication for risperidone were recorded
from the medical and pharmacy records. All dosages of psychos-
timulants were expressed in methylphenidate equivalents for am-
phetamines (·2).
During the study entry and follow-up research visits, height was
measured to the nearest 0.1 cm using a stadiometer (Holtain Ltd.,
UK) and weight was recorded to the nearest 0.1 kg using a digital
scale (Scaletronix, Wheaton, IL) while the subjects were wearing
indoor clothes without shoes. Vital signs were obtained with the
subject in the sitting position, after 15 minutes of rest. Triceps and
subscapular skinfold thickness was measured with a Lange skinfold
caliper to the nearest 0.1 mm (Calarge et al. 2009a; Centers for
Disease Control 2000). Waist circumference was measured to the
nearest 0.1 cm with the measuring tape placed at the uppermost
lateral border of the right iliac crest (Calarge et al. 2009a). The
average of two measurements was used. In addition, the medical
record was reviewed to extract all height and weight measurements,
including the measurements closest (i.e., within 0–30 days) to when
risperidone treatment was begun. When both were available, BMI
(kg/m2) was computed. As reported elsewhere (Calarge et al.
2012b), we observed excellent correlations between research-based
anthropometric measurements and those recorded during clinical
encounters falling within 1 month of the research visits.
Pubertal stage was evaluated by a physician. Independently, the
participants, with parental help when necessary, completed a self-
assessment form that included age-appropriate instructions and
pictures depicting Tanner stages I–V. As interrater agreement be-
tween the physician and self-rating was high (Calarge et al. 2009a),
self-rating was used for participants who declined to undergo this
examination.
A best-estimate diagnosis, following the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th ed., Text Revision (DSM-
IV-TR) (American Psychiatric Association 2000), was generated
based on a review of the psychiatric record, often supplemented by
a clinical interview (conducted by C.A.C.), a standardized inter-
view of the parent using the National Institute for Mental Health
(NIMH) Diagnostic Interview Schedule for Children (DISC-IV)
(Shaffer et al. 2000), and the Child Behavior Checklist (Achenbach
and Rescorla 2001).
At each of the research visits, a blood sample was obtained, after
a 9 hour overnight fast, to measure glucose, total insulin, C-peptide,
total cholesterol, high-density lipoprotein (HDL) cholesterol, tri-
glycerides, leptin, adiponectin, high-sensitivity C-reactive protein
(hsCRP), interleukin-6 (IL-6), thyroid stimulating hormone (TSH),
prolactin, and trough serum risperidone and 9-hydroxyrisperidone
concentrations (referred to, henceforth, as risperidone concentra-
tion). Some of the assays were added at a later point in the study,
making them available at study entry for a subsample. Low-density
lipoprotein (LDL) cholesterol was estimated following Friede-
wald’s equation (Friedewald et al. 1972). Measurements from
participants who were either not fasting or whose fasting status was
not recorded were excluded from the relevant analyses, except for
prolactin, TSH, IL-6, and hsCRP.
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Data analysis
To account for the natural growth observed in children and ado-
lescents monitored over extended periods, weight and BMI mea-
surements were converted into age-sex-specific z scores and
percentiles using the 2000 Centers for Disease Control and Preven-
tion normative data (Ogden et al. 2002). Overweight was defined as a
BMI percentile between 85 and 95 and obese was defined as a BMI
percentile ‡ 95. Blood pressure measurements were converted to
age-sex-height-specific z-scores (Falkner and Daniels 2004). Body
fat content was estimated using skinfold thickness measurements
following Slaughter et al. (1988), and the homeostasis model as-
sessment insulin resistance index (HOMA-IR) was estimated as:
[insulin (lUI/mL) · glucose (mg/dL)]/405 (Matthews et al. 1985).
A HOMA-IR cutoff of 4.39 was used to denote insulin resistance in
adolescents (i.e., age >12 years) (Lee et al. 2006). The presence of
metabolic syndrome was defined using cutoffs listed in Table 1,
following Cook et al. (2003). Using the laboratory-determined nor-
mal ranges, hyperprolactinemia was defined as a prolactin concen-
tration >15.2 ng/mL in males and >23.3 ng/mL in females.
As will be detailed, most of the participants remained on risper-
idone at the follow-up visit (Risp Cont group, n= 74), one subgroup
switched to another SGA (SGA Cont group, n= 9), and another
subgroup discontinued all SGA treatment (SGA Disc group, n= 18).
Fisher’s exact test was used to compare categorical variables across
the three groups at study entry and the follow-up visit, and multi-
variable linear regression analysis was used to compare continuous
variables, while accounting for age and sex where appropriate.
Variables not normally distributed were natural log transformed.
Between study entry and follow-up, a median 8 BMI measure-
ments per participant were available (range 2–19, interquartile range:
6–10). Therefore, to model BMI z score change across the three SGA
treatment groups, a hierarchical linear mixed model analysis was
used to fit the trajectory of BMI z score over time by estimating a
mean curve for BMI z score over time, across each SGA treatment
group, from the individual curve of each subject. Thus, the model
included both fixed and random effects for intercept and slope (i.e.,
time), to represent the mean curve and the random variation of each
subject’s curve from the mean curve, respectively. Informed by our
previous work (Calarge et al. 2012a), the model included BMI z
score at study entry, sex, treatment with selective serotonin reuptake
inhibitors (SSRIs), weight-adjusted (mg/kg) daily dose of psychos-
timulants, and follow-up SGA treatment status, along with a time by
follow-up SGA treatment status interaction effect. The latter inter-
action effect captures whether the trajectory of BMI z score over time
differs across the three SGA treatment groups.
All hypothesis tests were two tailed and analyses utilized pro-




Of 151 participants who entered the study, 108 (72%) returned
for the follow-up visit after 1.49 – 0.29 years. Of those, three were
excluded from further analyses as their serum risperidone con-
centration at study entry or follow-up was below the detection limit,
suggesting treatment nonadherence. Four other participants were
excluded because of the onset of hypothyroidism (n = 3) or type 1
diabetes. Participants who returned for follow-up did not differ
from those who dropped out of the study on multiple demographic
and clinical characteristics including age, BMI z score or obesity
status at study entry, and duration of risperidone treatment. How-
ever, those who returned for follow-up were more likely to be male
(93% vs. 79%, p< 0.02), have an autism spectrum disorder (18%
vs. 2%, p< 0.02), and have been receiving an antidepressant (63%
vs. 40%, p< 0.02). In addition, they were less likely to have had a
history of reported abuse or neglect (6% vs. 16%, p= 0.05).
At the follow-up visit, the majority (73%) had continued to take
risperidone (Risp Cont Group), with 18% discontinuing all SGA
treatment (SGA Disc Group) and 9% switching to another SGA
(SGA Cont Group). The latter group included youths treated with
different SGAs combined into a single group because of the small
number of participants per drug (aripiprazole n= 3, ziprasidone n= 2,
clozapine n= 2, quetiapine n= 1, and olanzapine n= 1). Tables 2 and
3 describe the demographic and clinical characteristics of the
participants split into the three SGA treatment groups. No signifi-
cant clinical differences existed across the three SGA treatment
groups at study entry, except for a marginally higher rate of
Table 1. Prevalence of Cardiometabolic Abnormalities
in the Sample Grouped by Second-Generation
Antipsychotic (SGA) Treatment Status
at Follow-upa
Risp Cont SGA Cont SGA Disc
n= 74 n = 9 n= 18 p valueb
Waist circumference ‡ 90th percentile, n (%)
At study entry 5 (7) 2 (25) 1 (6) > 0.20
At follow-up 7 (10) 4 (50) 1 (6) < 0.02
Systolic or diastolic blood pressure ‡ 90th percentile, n (%)
At study entry 7 (10) 1 (11) 2 (11) 1.0
At follow-up 11 (16) 4 (44) 3 (17) > 0.10
Glucose ‡ 100 mg/dL, n (%)
At study entry 7 (10) 0 4 (25) > 0.20
At follow-up 7 (11) 2 (22) 0 > 0.10
Insulin ‡ 22lIU/mL, n (%)
At study entry 1 (2) 1 (13) 0 > 0.20
At follow-up 3 (5) 0 1 (6) 1.0
HOMA-IR > 4.39, n (%)c
At study entry 2 (6) 0 0 1.0
At follow-up 2 (5) 1 (25) 1 (9) > 0.20
Triglycerides ‡ 110 mg/dL, n (%)
At study entry 3 (4) 1 (13) 2 (13) > 0.20
At follow-up 9 (14) 4 (44) 2 (13) < 0.09
HDL Cholesterol £ 40 mg/dL, n (%)
At study entry 6 (9) 1 (13) 0 > 0.40
At follow-up 11 (17) 2 (22) 2 (13) > 0.80
‡1 Metabolic syndrome criteria, n (%)d
At study entry 16 (24) 3 (38) 6 (38) > 0.40
At follow-up 28 (44) 7 (78) 6 (38) > 0.10
Metabolic syndrome, n (%)d
At study entry 2 (3) 0 0 1.0
At follow-up 4 (6) 2 (22) 0 < 0.1
aLaboratory results are reported only for participants who were fasting:
n = 70, 9, and 16, respectively, at study entry and n = 66, 10, and 16,
respectively, at follow-up.
bSignificant findings are bolded, and findings that are marginally
significant are bolded and italicized.
cThe homeostasis model assessment insulin resistance index (HOMA-
IR) was defined categorically only in adolescent participants (i.e., age >12
years) (Lee et al. 2006).
dThis variable includes abnormal waist circumference, systolic and
diastolic blood pressure, glucose, triglycerides, and high-density lipoprotein
(HDL) cholesterol as defined in this Table (Cook et al. 2003).
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disruptive behavior disorders in the Risp Cont Group and a sig-
nificantly higher weight-adjusted dose of risperidone in the SGA
Cont Group.
Anthropometric outcomes
As shown in Table 2, no significant between-group difference in
BMI z score was observed either at the onset of risperidone treat-
ment or at study entry. However, at the follow-up visit, the SGA
Cont Group had a significantly higher BMI z score than the other
two groups (both p£ 0.0005), which did not differ from one an-
other. Interestingly, the SGA Cont Group exhibited a greater in-
crease in BMI z score between the onset of risperidone treatment
and study entry than did the Risp Cont Group (least squares [LS]
mean difference: 0.83, 95% confidence interval [CI]: 0.13, 1.54)
and the SGA Disc Group (LS mean difference: 0.82, 95% CI: 0.00,
Table 2. Demographic and Anthropometric Characteristics of the Sample Grouped
by Second-Generation Antipsychotic Treatment Status at Follow-up
Risp Cont SGA Cont SGA Disc
n= 74 n= 9 n= 18 p valuea
Males, n (%) 70 (95) 8 (89) 16 (89) > 0.30
Race/Ethnicity, n (%) > 0.20
White 59 (80) 6 (67) 17 (94)
African American 11 (15) 2 (22) 0
Other 2 (3) 0 0
Hispanic 2 (3) 1 (11) 1 (6)
Age, years
At study entry 11.8 – 2.7 10.7 – 2.5 11.5 – 2.3 > 0.40
At follow-up 13.3 – 2.7 12.3 – 2.6 13.1 – 2.3 > 0.50
Tanner stage, % I/II/III/IV/V
At study entry 36/18/18/23/5 33/22/44/0/0 28/33/6/33/0 > 0.20
At follow-up 15/22/18/14/31 22/33/0/22/22 17/17/6/33/28 > 0.50
Anthropometric measures
Body Mass Index z score
At start of risperidoneb 0.05 – 1.03 - 0.19 – 1.41 0.25 – 1.07 > 0.60
At study entry 0.36 – 1.11 0.98 – 1.41 0.66 – 0.73 > 0.10
At follow-up 0.32 – 1.11 1.66 – 0.57 0.12 – 0.92 0.001
Annual rate of change - 0.02 – 0.34 0.40 – 0.56 - 0.35 – 0.41 < 0.001
Overweight, n (%)
At Start of risperidoneb 9 (17) 1 (14) 0 > 0.20
At study entry 13 (18) 2 (22) 4 (22) > 0.70
At follow-up 10 (14) 2 (22) 2 (11) > 0.70
Obese, n (%)
At Start of risperidoneb 2 (4) 0 2 (15) > 0.10
At study entry 7 (10) 3 (33) 2 (11) > 0.10
At follow-up 10 (14) 5 (55) 1 (6) < 0.006
Waist circumference, cmc
At study entry 70.9 – 13.9 75.6 – 16.5 71.1 – 10.1 > 0.20
At follow-up 75.1 – 15.2 90.0 – 11.9 70.7 – 11.2 0.0005
Percent body fatc
At study entry 19.4 – 9.5 24.6 – 14.3 21.7 – 8.3 > 0.20
At follow-up 19.1 – 10.2 30.1 – 11.4 16.9 – 8.9 < 0.007
Heart rate, bpmc
At study entry 85.7 – 13.7 85.3 – 10.2 85.3 – 12.1 > 0.90
At follow-up 81.5 – 13.1 83.9 – 19.3 77.2 – 14.2 > 0.30
Pulse pressure, mmHgc
At study entry 46.0 – 10.0 42.8 – 9.8 47.7 – 11.5 > 0.50
At follow-up 46.3 – 11.0 52.0 – 13.5 51.3 – 13.0 < 0.09
Systolic blood pressure z score
At study entry - 0.02 – 0.95 - 0.00 – 0.98 0.38 – 0.98 > 0.20
At follow-up - 0.19 – 1.16 1.02 – 1.96 0.21 – 1.14 < 0.02
Diastolic blood pressure z score
At study entry - 0.15 – 0.72 0.07 – 0.79 0.04 – 0.58 > 0.40
At follow-up - 0.18 – 0.88 0.42 – 0.89 - 0.24 – 0.75 > 0.10
Values are reported as mean– sd or n (%).
aSignificant findings are bolded and findings that are marginally significant are bolded and italicized.
bData are available for n = 52, 7, and 13, across the three groups, respectively.
cAdjusted for age and sex.
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1.64), which did not differ from each other (LS mean difference:
0.01, 95% CI: - 0.53, 0.56).
After adjusting for age and sex, the SGA Disc Group gained
significant weight (+ 5.0 kg, 95% CI: 1.6, 8.3) between study entry
and follow-up, which was not different ( p> 0.20) from the weight
gained by the Risp Cont Group (+ 6.9 kg, 95% CI: 4.4, 9.4) but it was
significantly less ( p< 0.0001) than that gained by the SGA Cont
Group (+ 17.5 kg, 95% CI: 13.1, 21.9). However, whereas the BMI in
the SGA Disc Group did not significantly change (-0.36 kg/m2, 95%
CI: -1.30, 0.58) between study entry and follow-up, after adjusting
for age and sex, that of the other two groups significantly increased
(Risp Cont Group: + 0.93 kg/m2, 95% CI: 0.23, 1.64 and SGA Cont
Group: + 3.99 kg/m2, 95% CI: 2.76, 5.23). Taking age-appropriate
growth into account, this translated into a reversal of the age-sex-
specific BMI z scores in the SGA Disc Group to the pre-risperidone
level (- 0.54, 95% CI: - 0.80, - 0.28), the maintenance of the BMI z
Table 3. Clinical Characteristics of the Sample Grouped by Second-Generation Antipsychotic (SGA)
Treatment Status at Follow-up
Risp Cont SGA Cont SGA Disc
n= 74 n= 9 n = 18 p valuea
Disruptive behavior disorder, n (%) 68 (92) 7 (78) 14 (78) < 0.09
Attention-deficit/hyperactivity disorder, n (%) 65 (88) 7 (78) 17 (94) > 0.30
Anxiety disorder, n (%) 23 (31) 3 (33) 5 (28) 1.0
Depressive disorder, n (%) 3 (4) 0 2 (11) > 0.20
Autism spectrum disorder, n (%) 12 (16) 2 (22) 5 (28) > 0.40
Tic disorder, n (%) 17 (23) 3 (33) 5 (28) > 0.70
Pharmacotherapy
Duration of risperidone treatment, yearsb
At study entry 2.64 – 1.65 1.97 – 1.58 1.91 – 1.34 > 0.10
At follow-up 4.05 – 1.70 2.47 – 1.60 2.39 – 1.52 < 0.0001
Risperidone dose, mg/kg/db
At study entry 0.03 – 0.02 0.04 – 0.02 0.02 – 0.02 < 0.02
At follow-up 0.03 – 0.02 — — —
Psychostimulants, n (%)
At study entry 52 (70) 4 (44) 14 (78) > 0.20
At follow-up 59 (80) 5 (56) 11 (61) > 0.10
a2-agonists, n (%)
At study entry 23 (31) 4 (44) 4 (22) > 0.50
At follow-up 25 (34) 6 (67) 5 (28) > 0.10
Antidepressants, n (%)
At study entry 45 (61) 6 (67) 14 (78) > 0.40
At follow-up 43 (58) 8 (89) 10 (56) > 0.10
Mood stabilizers, n (%)
At study entry 5 (7) 0 0 > 0.70
At follow-up 6 (8) 0 2 (11) > 0.60
aSignificant findings are bolded and findings that are marginally significant are bolded and italicized.
bAdjusted for age and sex.
FIG. 1. Trajectory of body mass index (BMI) z score across those who remained on risperidone, switched to another second-
generation antipsychotic (SGA), or discontinued SGAs
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scores in the Risp Cont Group (-0.04, 95% CI: - 0.16, 0.09), and a
further increase in BMI z scores in the SGA Cont Group (+ 0.68,
95% CI: 0.31, 1.04). After adjusting for BMI z score at study entry
(b= 0.91, p< 0.0001), male sex (b= - 0.00, p> 0.90), SSRI treat-
ment (b= - 0.17, p< 0.0001), and the weight-adjusted dose of psy-
chostimulants (b= - 0.18, p< 0.0001), there was a significant time
by SGA treatment group interaction effect whereby the BMI z score
significantly decreased over time in the SGA Disc Group (b= - 0.19,
p< 0.004) but significantly increased in the SGA Cont Group
(b= 0.26, p< 0.003) compared with the Risp Cont Group (Fig. 1).
The differential trajectory in BMI z score over time translated into
nearly triple the rate of overweight and obesity in the SGA Cont
Group (78%) compared with the other two groups (27% for the Risp
Cont Group and 17% for the SGA Disc Group, respectively,
p= 0.004). As would then be expected, at follow-up, the SGA Cont
Group also had significantly larger waist circumference and percent
body fat as well as higher age-sex-height-specific systolic blood
pressure z score (Table 2). The change in BMI z score between study
entry and follow-up in the entire sample was positively correlated
with change in systolic and diastolic blood pressure z scores
(Spearman’s q= 0.20, p< 0.06 and q= 0.26, p< 0.02, respectively)
and, after adjusting for age and sex, with heart rate (Spearman’s
q= 0.28, p< 0.006), waist circumference (Spearman’s q= 0.74,
p< 0.0001), and percent body fat (Spearman’s q= 0.62, p< 0.0001).
Cardiometabolic outcomes
The change in age-sex-specific BMI z score between the two
research visits (i.e., at study entry and follow-up) was significantly
correlated with the age-sex-adjusted change in a number of cardi-
ometabolic outcomes including total insulin (Pearson’s q = 0.26,
p < 0.03), HOMA-IR (Pearson’s q = 0.22, p < 0.07), C-peptide
(Pearson’s q = 0.38, p< 0.03), total cholesterol (Pearson’s q = 0.25,
p < 0.03), LDL cholesterol (Pearson’s q = 0.33, p< 0.004), HDL
cholesterol (Pearson’s q= - 0.25, p < 0.03), triglycerides (Pear-
son’s q = 0.25, p< 0.03), and triglycerides/HDL ratio (Pearson’s
q = 0.24, p < 0.04). It was also correlated with change in leptin
(Pearson’s q= 0.55, p < 0.0001), IL-6 (Pearson’s q = 0.38, p< 0.02),
and hsCRP (Spearman’s q= 0.27, p< 0.08).
When compared across the three SGA treatment groups, several
significant or marginally significant differences in the cardiometa-
bolic parameters emerged, with the SGA Cont group being different
from the two other groups, which did not differ from each other
(Tables 1 and 4). In addition, whereas total cholesterol increased
between the two research visits in the SGA Cont Group (+ 14.5 mg/
dL), it decreased in the Risp Cont Group (- 2.7 mg/dL, p< 0.05) and
the SGA Disc Group (- 9.4 mg/dL, p< 0.02). Similarly, the change
in LDL cholesterol was larger in the SGA Cont Group than in the
other two groups (+ 18.8 mg/dL vs. -1.4 mg/dL and - 4.6 mg/dL,
both p< 0.003). Overall, there was a marginally higher rate of met-
abolic syndrome in the SGA Cont Group at follow-up (Table 1).
Hormonal outcomes
Prolactin concentration was higher at follow-up in the Risp Cont
Group than in the other two groups (both p < 0.007). In fact, al-
though there was no difference across the three SGA treatment
groups in the rate of hyperprolactinemia at study entry ( p> 0.60),
none of the participants in either the SGA Disc or the SGA Cont
Group had this hormonal abnormality at follow-up, whereas 47% of
those in the Risp Cont Group did ( p < 0.0001). On the other hand,
TSH concentration did not differ among the three groups. However,
whereas*14% of the participants had a TSH above the laboratory-
determined cutoff for normal of 4.20 lIU/mL at study entry, sim-
ilarly distributed across the SGA treatment groups ( p> 0.80), 7%
had elevated TSH at follow-up, all in the Risp Cont Group.
Nonetheless, this difference was not significant ( p> 0.40). It is of
note that the highest TSH value was 8.91 lIU/mL; notably, how-
ever, participants with hypothyroidism were excluded from the
analyses as described earlier.
Discussion
To our knowledge, this is the largest observational study to date
monitoring metabolic outcomes in children and adolescents treated
with SGAs for several years. Using a largely overlapping sample,
we previously reported that substantial weight gain occurs fol-
lowing the initiation of risperidone treatment (Calarge et al. 2009a)
and identified clinical, pharmacological, and genetic variables that
may moderate weight gain (Calarge et al. 2009c, Calarge et al.
2012a). We further proposed that the rate at which weight is gained
impacts the severity of cardiometabolic abnormalities (Calarge
et al. 2012b). The primary finding of the current analysis is that
after an initial mean 2.4 years of treatment, risperidone continua-
tion is associated with persistence of excessive weight, whereas
risperidone discontinuation leads to the normalization of weight.
This is not to say that the SGA Disc Group actually lost weight
between study entry and follow-up. In fact, they gained weight, but
at a lower rate, commensurate with necessary gain for normal
growth and development. This allowed them to achieve a negative
energy balance and their age-sex-specific BMI z scores to nor-
malize. We further found that change in BMI z score over the study
period impacted cardiometabolic parameters in predictable ways.
A comprehensive assessment of factors associated with SGA
treatment continuation is beyond the aims of this study. Across
multiple variables, summarized in Tables 1–4, no significant dif-
ferences were identified between the Risp Cont and SGA Disc
Groups, whether at the onset of risperidone treatment or study
entry. On the other hand, the SGA Cont group appears to have been
receiving a higher weight-adjusted dose of risperidone at study
entry and to have had a larger increase in BMI z score since the
initiation of risperidone. These two characteristics may be related
in light of evidence suggesting that weight gain during risperidone
treatment is dose dependent (Correll et al. 2009; Gentile 2009).
However, neither the cumulative exposure period to risperidone nor
the cumulative dose of risperidone over that period differed across
the three SGA treatment groups (data available from the authors).
This is consistent with our prior finding that the dose effect of
risperidone on weight gain attenuates over time, as excessive
weight plateaus (Calarge et al. 2012a). It is of note that whereas
discontinuing risperidone was attributed by the physician or the
family to weight gain in 56% of the SGA Cont Group, this was the
case for only 6% of the SGA Disc Group ( p< 0.0002). In contrast,
31% of the SGA Disc Group reported that risperidone was no
longer necessary as a reason for discontinuation compared to none
of the SGA Cont Group ( p< 0.0002). This suggests that various
considerations, including clinical improvement, underlie the deci-
sion to discontinue SGA treatment. In contrast, the decision to
switch to an alternate SGA agent appears to be primarily motivated
by adverse events, in particular weight gain. Our data show that
substitution with another SGA provides no improvement in weight
status at best and, in many instances, it is actually associated with
additional weight gain. In fact, the participants who switched SGAs
exhibited varying degrees of change in BMI z score between study
entry and follow-up depending upon the alternative SGA they were
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Table 4. Cardiometabolic and Hormonal Laboratory Tests in the Sample Grouped by Second-Generation
Antipsychotic Treatment Status at Follow-upa
Risp Cont SGA Cont SGA Disc
n= 74 n= 9 n = 18 p valueb
Glucose, mg/dL
At study entry 91.4 – 9.9 91.3 – 4.0 91.6 – 8.5 > 0.90
At follow-up 89.6 – 10.3 91.4 – 25.0 90.0 – 5.0 > 0.80
C-peptide, ng/mL
At study entry 1.7 – 0.7 1.8 – 0.8 1.5 – 0.2 > 0.60
At follow-up 1.8 – 0.9 2.7 – 0.8 1.8 – 0.7 0.002
Insulin, lIU/mL
At study entry 6.9 – 5.0 8.2 – 6.5 6.3 – 3.1 > 0.60
At follow-up 7.2 – 6.9 10.0 – 3.6 7.6 – 6.1 < 0.06
HOMA-IRc
At study entry 1.58 – 1.20 1.86 – 1.54 1.46 – 0.75 > 0.60
At follow-up 1.57 – 1.59 2.40 – 1.52 1.68 – 1.39 < 0.06
Total cholesterol, mg/dL
At study entry 156.6– 26.4 148.5– 12.5 164.6– 28.6 > 0.20
At follow-up 155.4– 24.6 162.8– 19.2 163.7– 38.7 > 0.70
LDL cholesterol, mg/dL
At study entry 86.5 – 22.0 78.4 – 19.1 94.4 – 26.6 > 0.20
At follow-up 86.4 – 19.5 95.6 – 24.3 95.1 – 29.2 > 0.30
HDL cholesterol, mg/dL
At study entry 59.3 – 14.9 55.9 – 15.5 55.5 – 12.6 > 0.30
At follow-up 55.5 – 15.7 49.3 – 8.8 52.5 – 16.5 > 0.10
Triglycerides, mg/dL
At study entry 59.9 – 73.2 71.4 – 40.1 73.6 – 49.5 < 0.07
At follow-up 70.1 – 67.0 94.8 – 54.6 77.2 – 56.7 < 0.10
Triglycerides/HDL cholesterol
At study entry 1.23 – 1.98 1.41 – 0.90 1.48 – 1.27 < 0.08
At follow-up 1.61 – 2.34 2.10 – 1.46 1.68 – 1.61 < 0.08
Leptin, ng/mL
At study entry 4.8 – 4.5 7.5 – 5.7 6.3 – 6.1 > 0.20
At follow-up 5.6 – 5.7 15.5 – 9.9 4.6 – 5.1 < 0.002
Adiponectin, lg/mL
At study entry 16.3 – 6.9 12.5 – 6.1 14.6 – 7.1 > 0.30
At follow-up 13.3 – 6.1 9.3 – 3.4 14.8 – 8.9 0.05
Interleukin-6, pg/mL
At study entry 1.16 – 0.87 1.03 – 0.92 0.84 – 0.50 > 0.40
At follow-up 1.20 – 1.30 1.40 – 0.98 1.13 – 1.10 > 0.70
hs CRP, mg/L
At study entry 0.86 – 1.86 0.24 – 0.12 0.37 – 0.39 > 0.90
At follow-up 0.81 – 1.87 1.30 – 1.61 0.50 – 1.2 > 0.10
Thyroid stimulating hormone, lIU/mL
At study entry 2.7 – 1.3 2.4 – 1.1 2.2 – 1.2 > 0.20
At follow-up 2.7 – 1.3 2.7 – 1.2 1.9 – 0.7 > 0.10
Prolactin, ng/mL
At study entry 21.5 – 15.3 28.7 – 14.8 22.4 – 17.3 > 0.50
At follow-up 18.2 – 14.1 6.7 – 6.2 5.8 – 3.1 < 0.0001
aAll analyses were adjusted for age and sex. Except for high sensitivity C-reactive protein (hs CRP), interleukin 6, thyroid stimulating hormone, and
prolactin, laboratory results are reported only for participants who were fasting: n = 67, 8, and 16, respectively, at study entry and n = 63, 9, and 16 at
follow-up. Interleukin-6, hs CRP, and adiponectin were added while the study was ongoing, making them available for 34, 4, and 5 participants,
respectively, at study entry.
bSignificant findings are bolded and findings that are marginally significant are bolded and italicized.
cThe homeostasis model assessment insulin resistance index.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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prescribed (aripiprazole, n= 3, BMI z score change = 0.2 – 0.2; zi-
prasidone, n= 2, D = 0.0 – 0.1; clozapine, n = 2, D = 2.0 – 1.5; que-
tiapine, n= 1, D= 0.5; and olanzapine, n = 1, D = 1.0); however,
none actually had a decline in BMI z score. Therefore, it appears
that children and adolescents who gain substantial weight on ris-
peridone are equally likely to gain excessive weight on other SGAs.
The cardiovascular sequelae of excessive weight are well es-
tablished (Wormser et al. 2011). Moreover, weight loss interven-
tions have been shown to improve cardiovascular parameters
(Norris et al. 2005; Rucker et al. 2007; De Miguel-Etayo et al.
2013). Therefore, it was not surprising to see all cardiometabolic
markers, including blood pressure, insulin resistance, lipid pa-
rameters, and even inflammatory markers, change in correlation
with the change in BMI z score. It is reassuring that despite
maintaining excessive weight for several years, participants who
discontinued risperidone saw their BMI z score normalize and the
change was associated with an improvement in a host of cardio-
metabolic markers. This is consistent with findings from clinical
trials switching youth and adults from one SGA to another with the
potential to cause less weight gain, as well as with findings from
weight loss interventions in which idiopathic obesity had been
present presumably for years (Norris et al. 2005; Rucker et al. 2007;
Rosenheck et al. 2009; Mukundan et al. 2010).
We and others have found prolactin concentration to be closely
tied to the dose of risperidone (Kinon et al. 2003; Calarge et al.
2009b). At follow-up, prolactin concentration was strongly corre-
lated with risperidone concentration (Pearson’s q= 0.56, p< 0.0001)
and the change in prolactin between study entry and follow-up was
strikingly different across the three SGA treatment groups. Con-
sistent with our previous findings and those of others (Findling et al.
2003; Kinon et al. 2003; Calarge et al. 2009b), hyperprolactinemia
persisted in *50% of the risperidone-treated children and adoles-
cents, even after nearly 4 years of treatment. To what extent this may
adversely impact health and development requires further investi-
gation, particularly in light of some preclinical and clinical evidence,
including from our laboratory, suggesting that hyperprolactinemia is
inversely associated with bone mass (Calarge et al. 2010, 2013).
Thyroid dysfunction has been associated with both psychopa-
thology and the use of antipsychotic medications, particularly
quetiapine (Greenspan et al. 2005; Kelly and Conley 2005; Bou
Khalil and Richa 2011; Dickerman and Barnhill 2012). Although
we did not find significant differences in TSH concentration across
the three SGA treatment groups, it is concerning that three partic-
ipants were excluded from the analysis because of hypothyroidism,
and several participants, restricted to the Risp Cont Group, con-
tinued to show elevated TSH. Therefore, further research is nec-
essary to investigate this preliminary finding and examine whether
it is related to SGAs or the underlying psychopathology.
Our findings are important in many respects as reviewed;
nonetheless, their interpretation must take into account several
shortcomings. First, the study is observational, suggesting that a
variety of uncontrolled factors could explain the differences we
observed. Further, the participants had already received risperidone
for a minimum of 6 months before entering the study. Therefore, it
is unclear how our findings may apply to patients who had received
SGA treatment, risperidone or otherwise, for a shorter period of
time before discontinuing it. As discussed earlier, participants in
the SGA Cont Group switched from risperidone to one of several
SGAs with clearly different potential to cause weight gain and
cardiometabolic abnormalities. Merging them into a single group
was done for practical, as opposed to scientific, reasons, because of
the small sample size. Clearly, this would influence the findings
related to that group, but should not affect the results from the
correlational analyses examining the association between change in
BMI z score and cardiometabolic parameters. It should also not
affect the findings related to the SGA Disc Group, a primary focus
of this report. An additional related factor is that the discontinuation
of risperidone and, in the SGA Cont Group, the initiation of the new
SGA treatment, occurred at different times for different partici-
pants. Therefore, further anthropometric and metabolic changes
may still take place for at least some participants who have not
reached their new ‘‘homeostatic’’ set point. Finally, of those who
entered the study, 28% did not return for follow-up. This significant
attrition may also have impacted our findings, particularly as these
participants differed in certain demographic and clinical charac-
teristics (e.g., females) from those who completed the follow-up.
Conclusions
In sum, SGA treatment appears to alter the homeostatic set point
controlling energy balance whereby, despite interindividual vari-
ability, on average, the new equilibrium corresponds to a higher
BMI than is appropriate for age and sex. This new threshold seems
stable over time, at least for risperidone, as more extended treatment
does not appear to lead to further excessive weight gain. However,
discontinuation of the treatment results in a return to the baseline
BMI z score whereas switching to another SGA is associated with a
varying magnitude of BMI change, depending upon the propensity
of the particular new SGA to cause weight gain. Idiopathic obesity
responds to weight loss interventions, but the benefits subside over
the intermediate term. It is, therefore, reassuring that the discon-
tinuation of risperidone, particularly after years of use, is associated
with largely spontaneous resolution of the excessive weight and a
favorable change in cardiometabolic parameters.
Clinical Significance
Children and adolescents who discontinued risperidone lost the
excessive, age-inappropriate, weight they had gained on it. Further,
this was associated with an improvement in multiple cardiometa-
bolic parameters. Such findings are somewhat reassuring, particu-
larly considering that the participants had been in treatment for an
extended period. Nonetheless, because no demographic or clinical
characteristic at study entry helped predict who might discontinue
risperidone by follow-up, clinicians must remain vigilant about
following recommended guidelines for monitoring in order to
minimize the potential cardiovascular sequelae of SGAs, especially
when treatment is needed for years.
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